Unknown

Dataset Information

0

Setting minimum clinical performance specifications for tests based on disease prevalence and minimum acceptable positive and negative predictive values: Practical considerations applied to COVID-19 testing.


ABSTRACT:

Objectives

Several guidelines for the evaluation of laboratory tests for severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infection have recommended establishing an a priori definition of minimum clinical performance specifications before test selection and method evaluation.

Methods

Using positive (PPV) and negative predictive values (NPV), we constructed a spreadsheet tool for determining the minimum clinical specificity (conditional on NPV or PPV, sensitivity and prevalence) and minimum clinical sensitivity (conditional on NPV or PPV, specificity and prevalence) of tests.

Results

At a prevalence of 1%, there are no minimum sensitivity requirements to achieve a desired NPV of 60%-95% for a given clinical specificity above 20%. It is not possible to achieve 60-95% PPV even with 100% clinical sensitivity, except when the clinical specificity is near 100%. The opposite trend is seen in high prevalence settings (60%), where a relatively low minimum clinical sensitivity is required to achieve a desired PPV for a given clinical specificity, and a higher minimum clinical specificity is required to achieve a desired NPV for a given clinical sensitivity.

Discussion

The selection of laboratory tests and the testing strategy for SARS-CoV-2 involves delicate trade-offs between NPV and PPV based on prevalence and clinical sensitivity and clinical specificity. Practitioners and health authorities should carefully consider the clinical scenarios under which the test result will be used and select the most appropriate testing strategy that fulfils the a priori defined clinical performance specification.

SUBMITTER: Loh TP 

PROVIDER: S-EPMC7678449 | biostudies-literature | 2021 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

Setting minimum clinical performance specifications for tests based on disease prevalence and minimum acceptable positive and negative predictive values: Practical considerations applied to COVID-19 testing.

Loh Tze Ping TP   Lord Sarah J SJ   Bell Katy K   Bohn Mary Kathryn MK   Lim Chun Yee CY   Markus Corey C   Fares Taie Hernan H   Adeli Khosrow K   Lippi Giuseppe G   Sandberg Sverre S   Horvath Andrea A  

Clinical biochemistry 20201120


<h4>Objectives</h4>Several guidelines for the evaluation of laboratory tests for severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infection have recommended establishing an a priori definition of minimum clinical performance specifications before test selection and method evaluation.<h4>Methods</h4>Using positive (PPV) and negative predictive values (NPV), we constructed a spreadsheet tool for determining the minimum clinical specificity (conditional on NPV or PPV, sensitivity and pr  ...[more]

Similar Datasets

| S-EPMC4207653 | biostudies-literature
| S-EPMC7943825 | biostudies-literature
| S-EPMC3367316 | biostudies-literature
| S-EPMC6144161 | biostudies-literature
| S-EPMC8170576 | biostudies-literature
| S-EPMC7775938 | biostudies-literature
| S-EPMC7556561 | biostudies-literature
| S-EPMC6466924 | biostudies-literature
| S-EPMC5077142 | biostudies-literature
| S-EPMC6740030 | biostudies-literature